The MPTP model of Parkinson's disease.
The biochemical and cellular changes that occur following administration of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) are remarkably similar to that seen in idiopathic Parkinson's disease (PD). In this review, we detail the molecular activities of this compound from peripheral intoxication through its various biotransformations. In addition, we detail the interplay that occurs between the different cellular compartments (neurons and glia) that eventually consort to kill substantia nigra pars compacta (SNpc) neurons.
Smeyne
Richard Jay
RJ
Department of Developmental Neurobiology, Saint Jude Children's Research Hospital, Memphis, TN 39105, USA. richard.smeyne@stjude.org
Jackson-Lewis
Vernice
V
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D008954:Models, Biological; D009457:Neuroglia / Q000502:physiology; D009474:Neurons / Q000502:physiology; D010300:Parkinson Disease / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine